Personnel

Biotechnology company announces new member to board of directors

Published in Immunotherapy Weekly, February 4th, 2004

Favrille, Inc., announced that Peter Barton Hutt, a leading food and drug law expert and former chief counsel for the U.S. Food and Drug Administration (FDA), has joined the company's board of directors.

"His many years of experience in the field of drug and biologic regulatory law, his knowledge of the FDA, his law practice in Washington, D.C., and his past and current board memberships make Peter very valuable to Favrille as we move towards product commercialization," said John Longenecker, PhD, Favrille's president and chief executive officer.

Favrille is currently conducting Phase II clinical trials with the Company's lead investigational agent,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Immunotherapy Weekly

Source: Immunotherapy Weekly (2004-02-04)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry